SSShamin Mohd Saffian

Shamin Mohd Saffian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shamin Mohd Saffian has a total of 178 co-authors. Here are the top co-authors by number of shared publications:

  • Mohd Makmor-Bakry

    Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

    10 shared publications
  • Mohd Makmor-Bakry

    Centre for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

    5 shared publications
  • Nor Asyikin Mohd Tahir

    Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

    5 shared publications
  • Noraida Mohamed Shah

    Centre for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

    5 shared publications
  • Jian Lynn Lee

    Department of Pharmacy, Tunku Azizah Hospital, Ministry of Health Malaysia, Kuala Lumpur, Malaysia

    4 shared publications
  • Nor Asyikin Mohd Tahir

    Centre for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

    4 shared publications

Latest Publications

  • Meropenem Exposure, Target Attainment, and Therapeutic Drug Monitoring Practices in Critically Ill Adults Receiving Continuous Renal Replacement Therapy: A Systematic Review

    by Nazatul Adhwa Mohd Rozi, Lim Jia Hui, Shamin Saffian, Mohd Makmor-Bakry, Aliza Mohamad Yusof, Ruslinda Mustafar, Muhammad Nordin M Saud, Nor Asyikin Mohd Tahir

    Objective: To critically evaluate meropenem pharmacokinetics/pharmacodynamics (PK/PD) target attainment, therapeutic drug monitoring (TDM), infusion strategies, and clinical outcomes during continuous renal replacement therapy (CRRT). Data Sources: Ovid MEDLINE, PubMed, Scopus, Web of Science, and the Cochrane Library were searched from inception to August 15, 2026, using meropenem, TDM, β-lactam, and CRRT terms, with adult, human, and English-language limits. Study Selection and Data Extraction: Thirteen reports representing 12 unique studies (2 randomized, 10 non-randomized) reporting meropenem concentration data during CRRT were included. Two reviewers independently screened studies, extracted data, and assessed risk of bias using RoB 2 or ROBINS-I. Data Synthesis: Total clearance ranged from 3.60 to 6.6 L/h. Lower or primary PK/PD target non-attainment ranged from 0% to 26.7%, while aggressive-target non-attainment ranged from 0% to 53.3% in most analyses and reached 93% in 1 study when a minimum inhibitory concentration (MIC) of 8 mg/L was assumed. Continuous or prolonged infusion may facilitate sustained exposure, but comparative evidence was limited. Four used routine TDM; only 2 implemented protocolized TDM-guided dose adjustment. Low exposure was associated with higher mortality in 1 adjusted observational analysis, but evidence for clinical outcomes was of very low certainty. Relevance to Patient Care and Clinical Practice: Standardized meropenem regimens cannot be assumed to provide consistent exposure during CRRT. Optimized infusion and timely, protocolized TDM may support individualized dosing when multidisciplinary expertise is available. Conclusions: Available evidence supports a shift from standardized empirical dosing toward individualized, measurement-guided meropenem therapy in patients receiving CRRT.

  • Population pharmacokinetic model of high-dose methotrexate in Malaysian adults with hematological malignancies

    by Tuan Fauziah Tuan-Roslli, Mohd H Abdul-Aziz, Mohd Makmor-Bakry, Noraida Mohamed Shah, Shamin Mohd Saffian

  • Population Pharmacokinetics of Amikacin in Non-Neonatal Pediatric Patients: A Scoping Review

    by Chin Chiang Toh, Mohd Makmor Bakry, Noraida Mohamed Shah, Shamin Mohd Saffian

    Background Amikacin remains an important agent in managing severe Gram-negative infections in children. However, its clinical use is limited by a narrow therapeutic index and pronounced pharmacokinetic (PK) variability. Population pharmacokinetic (PopPK) modeling offers a framework for individualized dosing, yet evidence in non-neonatal pediatric populations remains fragmented. Methods A scoping review was conducted across PubMed, Scopus, and Web of Science (last updated July 2025) to identify PopPK studies evaluating intravenous amikacin in children aged 1 month to 18 years. Eligible studies applied nonlinear mixed effects modeling and reported structural models, PK parameters, and covariate analyses. Methodological quality was assessed using a 38-item checklist adapted from established guidelines. Results Of 783 records screened, 8 studies met the inclusion criteria. Most were retrospective, with sparse PK sampling from routine therapeutic drug monitoring (TDM) data. Body weight was the most consistently identified predictor, while renal function, age, and disease state were retained in selected models. Burn, cystic fibrosis, and oncology populations demonstrated consistently higher clearance and/or volume of distribution, often requiring higher doses for pharmacodynamic target attainment. None of the included studies performed external validation, limiting generalizability. Conclusions Amikacin PK in children is highly variable and disease-specific. Conventional weight-based dosing is frequently insufficient. Integration of model-informed precision dosing (MIPD) with TDM is essential to optimize amikacin therapy in pediatric practice, particularly in high-risk subpopulations.

  • Toxicity-Tailored Thresholds of Delayed Methotrexate Elimination in Non-Hodgkin Lymphoma: A Population-Based Approach to Therapy Optimization

    by Tuan Fauziah, Ganesh Kasinathan, Teng Keat Chew, Mohd Makmor-Bakry, Yi Lin Lee, Noraida Mohamed Shah, Shamin Mohd Saffian

    High-dose methotrexate (HDMTX) is an essential agent in hematological malignancies, the use of which is complicated by toxicities related to delayed elimination. Existing thresholds to define delayed elimination vary widely, creating inconsistencies in clinical practice. This multicenter retrospective study evaluated adult non-Hodgkin Lymphoma patients from Malaysia to establish a locally relevant delayed elimination threshold and identify factors influencing it. Patients who received HDMTX ≥ 500 mg/m2 were included. Data extracted from medical records were HDMTX regimen, supportive therapy, renal and liver function, full blood count, MTX concentrations, and MTX-related toxicities. MTX thresholds at 48 h were assessed based on their association with post-treatment clinical outcomes. The selected threshold was subsequently used to categorize patients into delayed and nondelayed elimination groups, and factors associated with delayed elimination were evaluated using logistic regression. A toxicity-based receiver operating characteristic (ROC) approach identified ≥ 0.2 µmol/L at 48 h as the concentration at which lymphocyte count and alanine aminotransferase (ALT) worsened by 50% and mucositis risk increased nearly threefold. Logistic regression showed increased baseline serum creatinine, decreased baseline albumin, and 24 h infusion duration as factors associated with delayed elimination, while Chinese ethnicity was associated with reduced odd of delayed elimination. These findings support a population-tailored threshold to better guide supportive management and highlight key predictors that can inform future pharmacokinetic modeling for optimized HDMTX therapy.

  • Open Access

    Amikacin pharmacokinetics, target attainment, and predictors in critically ill children: a retrospective cohort

    by Chin Chiang Toh, Jian Lynn Lee, Mohd Makmor Bakry, Noraida Mohamed Shah, Shamin Mohd Saffian

    We aimed to quantify amikacin pharmacokinetics (PK) and early target attainment using routine third-dose therapeutic drug monitoring (TDM) in pediatric intensive care unit (PICU) patients and to identify clinical covariates associated with volume of distribution (Vd) and clearance (CL). We conducted a retrospective cohort study of PICU patients who received intravenous amikacin between January 2022 and December 2023. Individual PK parameters were estimated using third-dose peak and trough concentrations via the Sawchuk-Zaske method. Clinical and laboratory covariates were evaluated for associations with Vd and CL. Among 210 patients, mean Vd was 0.59 ± 0.30 L/kg and mean CL was 0.08 ± 0.03 L/kg/h. Early target under attainment was frequent, with 23.3% of \({C}_{\text{max}}\) and 7.6% of \({C}_{\text{min}}\) values outside therapeutic targets. Independent predictors of Vd included age, creatinine clearance (CrCl), and alanine aminotransferase (ALT), while CL was independently associated with age, CrCl, urea, and ALT. Conclusion: Critically ill children demonstrate expanded Vd and increased CL, contributing to inadequate early amikacin exposure under standard dosing. Early PK-guided dosing and model-informed strategies may improve target attainment and individualized therapy in this high-risk population. What is Known: Amikacin PK in children is variable, and standard dosing may not consistently achieve therapeutic targets. Critically ill pediatric patients often experience altered drug disposition and clearance, which can affect amikacin exposure and response. What is New: This study quantified amikacin PK parameters in critically ill children receiving routine TDM in the PICU. Expanded Vd and increased CL were identified, with age, CrCl, urea, and ALT associated with variability in amikacin PK. What Is Known: • Amikacin PK in children is variable, and standard dosing may not consistently achieve therapeutic targets. • Critically ill pediatric patients often experience altered drug disposition and clearance, which can affect amikacin exposure and response. What Is New: • This study quantified amikacin PK parameters in critically ill children receiving routine TDM in the PICU. • Expanded Vd and increased CL were identified, with age, CrCl, urea, and ALT associated with variability in amikacin PK.


  • Population Pharmacokinetic Models of Oxypurinol in Adults: A Systematic Review

    by Farah Aida A. Zairol Azwan, Nor Asyikin Mohd Tahir, Shamin Mohd Saffian, Mohd Makmor-Bakry, Mohd Shahrir Mohamed Said

    Introduction: Allopurinol and its active metabolite, oxypurinol, reduce uric acid concentrations through xanthine oxidase inhibition by suppressing the conversion of hypoxanthine and xanthine. Oxypurinol plays a prominent role in allopurinol’s pharmacological activity due to its longer elimination half-life. Despite decades of clinical use, establishing an optimal dosing strategy to consistently achieve the target serum uric acid concentration lower than 0.36 mmol L-1 remains challenging. This review aimed to summarize the development of population pharmacokinetic modeling for oxypurinol and analyze factors influencing its pharmacokinetic variability. Methods: PubMed, Web of Science, and Scopus were systematically searched from database inception until January 2025, adhering to the PRISMA guideline. Studies were eligible if they involved oxypurinol population pharmacokinetic analyses in adults receiving allopurinol and employed nonlinear mixed-effects modeling Results: Eight studies met the inclusion criteria, mostly involving adult gout patients. Pharmacokinetic analyses of oxypurinol employed a one-compartment model, incorporating firstorder absorption and elimination, reporting clearance value of 0.60−1.74 L h-1 and volume of distribution 38.1−59.3 L. Covariates associated with oxypurinol clearance included creatinine clearance, body weight, normal fat mass, fat-free mass, ethnicity, genetic polymorphisms, and concomitant diuretics; whereas, total body weight was found as significant predictors for volume of distribution. Discussions: Reported values for oxypurinol clearance and volume of distribution varied across studies. The small sample sizes and underrepresentation of certain populations, particularly Asians, restrict the generalizability of these findings. Conclusion: Further research involving larger, more diverse cohorts is needed to refine therapeutic drug monitoring and identify potential covariates across different populations to optimize allopurinol therapy.


  • Open Access

    Neuroprotective Potential of SGLT2 Inhibitors in Animal Models of Alzheimer’s Disease and Type 2 Diabetes Mellitus: A Systematic Review

    by Azim Haikal Md Roslan, Tengku Marsya Hadaina Tengku Muhazan Shah, Shamin Mohd Saffian, Lisha Jenny John, Muhammad Danial Che Ramli, Che Mohd Nasril Che Mohd Nassir, Mohd Kaisan Mahadi, Zaw Myo Hein

    Background: Alzheimer’s disease (AD) features progressive cognitive decline and amyloid-beta (Aβ) accumulation. Insulin resistance in type 2 diabetes mellitus (T2DM) is increasingly recognised as a mechanistic link between metabolic dysfunction and neurodegeneration. Although sodium–glucose cotransporter-2 inhibitors (SGLT2is) have established glycaemic and cardioprotective benefits, their neuroprotective role remains less well defined. Objectives: This systematic review examines animal studies on the neuroprotective effects of SGLT2i in T2DM and AD models. Methods: A literature search was conducted across the Web of Science, Scopus, and PubMed databases, covering January 2014 to November 2024. Heterogeneity was assessed with I2, and data were pooled using fixed-effects models, reported as standardised mean differences with 95% confidence intervals. We focus on spatial memory performance as measured by the Morris Water Maze (MWM) test, including escape latency and time spent in the target quadrant, as the primary endpoints. The secondary endpoints of Aβ accumulation, oxidative stress, and inflammatory markers were also analysed and summarised. Results: Twelve studies met the inclusion criteria for this review. A meta-analysis showed that SGLT2i treatment significantly improved spatial memory by reducing the escape latency in both T2DM and AD models. In addition, SGLT2i yielded a significant improvement in spatial memory, as indicated by an increased target quadrant time for both T2DM and AD. Furthermore, SGLT2i reduced Aβ accumulation in the hippocampus and cortex, which met the secondary endpoint; the treatment also lessened oxidative stress and inflammatory markers in animal brains. Conclusions: Our findings indicate that SGLT2is confer consistent neuroprotective benefits in experimental T2DM and AD models.


  • Treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia patients receiving vancomycin: a retrospective study at a tertiary hospital

    by Zi Yin Fann, Ezazaya Othman, Siew Ling Chong, Shamin Mohd Saffian

    Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia remains a major clinical challenge with high mortality, despite guideline-recommended vancomycin therapy. Although a ratio of the area under the curve to the minimum inhibitory concentration (AUC/MIC) ≥400 mg·hour/L is advocated for efficacy, the association between pharmacokinetic/pharmacodynamic (PK/PD) target attainment and clinical outcomes remains uncertain. To determine the in-hospital mortality rate among patients with MRSA bacteraemia receiving vancomycin. The secondary objectives were to (1) evaluate the association between patient characteristics and in-hospital mortality, (2) examine the relationship between in-hospital mortality and secondary treatment outcomes, and (3) assess the impact of vancomycin AUC/MIC target attainment on in-hospital mortality. A retrospective cohort study was conducted at a tertiary hospital in Malaysia involving adults with MRSA bacteraemia treated from 2014 to 2024. AUC/MIC data were analysed for patients receiving intermittent vancomycin dosing. Multivariable logistic regression identified independent predictors of mortality. Among 148 patients included, the in-hospital mortality rate was 32.4% (n=48/148). Four factors were independently associated with in-hospital mortality: organ failure (adjusted OR (aOR) 19.28, 95% CI 5.14 to 72.26), recent antibiotic exposure (aOR 5.24, 95% CI 1.90 to 14.51), hypoalbuminaemia <30 g/L (aOR 4.56, 95% CI 1.69 to 13.06) and cerebrovascular disease (aOR 4.24, 95% CI 1.15 to 15.60). Subgroup analysis of patients on intermittent dosing revealed six independent predictors of in-hospital mortality: cerebrovascular disease (aOR 26.9, 95% CI 2.76 to 261.98), hypoalbuminaemia <30 g/L (aOR 10.68, 95% CI 1.54 to 74.29), organ failure (aOR 48.15, 95% CI 4.27 to 542.81), polymicrobial bacteraemia (aOR 24.28, 95% CI 3.09 to 190.64), persistent bacteraemia (aOR 90.08, 95% CI 2.85 to 2845.83) and intensive care unit admission (aOR 0.09, 95% CI 0.01 to 0.91), the latter showing a protective effect. Only 22.2% (n=26/117) achieved the target AUC/MIC, which was not significantly linked to mortality reduction. Vancomycin AUC/MIC attainment was suboptimal, and mortality was primarily influenced by host factors and disease severity. Early risk stratification and timely intervention are critical to improve outcomes and guide resource prioritisation, particularly in settings with limited access to AUC-guided dosing.


  • Delayed Elimination Concentrations of High-Dose Methotrexate in Adults With Hematological Malignancies: To Standardize or Not? A Scoping Review

    by Fauziah T, Ai Sim Goh, Noraida Mohamed Shah, Mohd Makmor-Bakry, Shamin Mohd Saffian

    Background: High-dose methotrexate (HDMTX) is a cornerstone therapeutic regimen for hematological malignancies; however, delayed elimination remains a significant clinical challenge. Currently, no standardized definition for delayed elimination exists. This scoping review aims to identify and characterize methotrexate elimination threshold variability and its implication on clinical data interpretation. Method: A literature search was conducted using PubMed, Scopus, and the Cochrane database to identify studies published in English from the 1960s to February 2025. All study types reporting delayed elimination thresholds for high-dose methotrexate in adult patients with hematological malignancies were included. Result: Twenty-three studies meeting the inclusion criteria were charted and summarized. The most frequently reported thresholds were 10 µmol/L at 24 hours (42%), 1 µmol/L at 48 hours (44%), and 0.1 µmol/L at 72 hours (55%). The threshold values varied widely at 24, 48, and 72 hours by 750-, 100-, and 3-folds, respectively. For most of the studies (87%), time measurement was initiated at the start of infusion. Majority of studies (81%) used immunoassays to quantify methotrexate, whereas 19% used liquid chromatography, with no significant difference in concentration thresholds observed between assay types. Conclusions: Significant variability exists in the thresholds used to define delayed HDMTX elimination, particularly at 48 hours, with the differences not explained by assay method. These inconsistencies affect clinical decisions, including toxicity predictions and rescue therapy implementation. Although standardization is needed to improve comparability, threshold definitions should also reflect population-specific pharmacokinetics and toxicity profiles to support more precise HDMTX monitoring and outcomes.


  • Open Access

    Bleeding Risk Prediction in Non-Valvular Atrial Fibrillation: Comparing Risk Scores in Apixaban- and Rivaroxaban-Treated Patients

    by Christian Andrew Almalbis, Adyani Md Redzuan, Shamin Mohd Saffian

    Objective: This study aimed to evaluate the ability of seven bleeding risk assessment tools to predict bleeding events in patients with apixaban or rivaroxaban. Methods: A retrospective analysis was conducted on 313 NVAF patients (apixaban: n = 164; rivaroxaban: n = 149) with at least one year of follow-up at a tertiary hospital in Malaysia. Bleeding risk scores were calculated at treatment initiation using original definitions. Bleeding events were defined according to ISTH criteria. Predictive performance was assessed via area under the receiver operating characteristic (AUROC) curves, with good diagnostic accuracy defined as AUROC ≥ 0.7. Subgroup analyses by age and sex were also performed. Results: Overall bleeding incidence was 12.46%. Among rivaroxaban users, ORBIT (AUROC 0.68), RE-LY (0.66), and HEMORR 2 HAGES (0.66) showed sufficient accuracy. For apixaban users, A4C performed best (AUROC 0.64); HAS-BLED showed no diagnostic value (AUROC 0.42). Some tools showed good subgroup accuracy. Conclusion: None of the bleeding risk assessment tools achieved good overall diagnostic accuracy in NVAF patients treated with apixaban or rivaroxaban. Further studies are needed to validate existing tools and to develop a bleeding risk score with acceptable diagnostic accuracy for this patient population.